Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 7/20 | 0.34 |
| ▸ | NOS1 | P29475 | 4/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021051 | 0.88 | CARM1 (0.35) | NOS2NOS1HTR6 | |
| SCHEMBL1021422 | 0.87 | TAAR1 (0.41) | TAAR1NOS2NOS1HTR6AOC3 | |
| SCHEMBL1022413 | 0.86 | ATM (0.38) | TAAR1NOS2NOS1 | |
| SCHEMBL1020728 | 0.85 | AOC3 (0.36) | TAAR1NOS2HTR6AOC3MAPK1 | |
| SCHEMBL1021224 | 0.85 | TAAR1 (0.46) | TAAR1NOS2NOS1HTR6 | |
| SCHEMBL13098768 | 0.85 | TAAR1 (0.39) | TAAR1NOS2HTR6SMN1; SMN2MAPK1 | |
| SCHEMBL1020159 | 0.85 | NOS2 (0.48) | NOS2HTR6AOC3SMN1; SMN2MAPK1 | |
| SCHEMBL1019346 | 0.84 | MPO (0.34) | NOS2NOS1 | |
| SCHEMBL1019398 | 0.80 | TAAR1 (0.43) | TAAR1HTR6AOC3 | |
| SCHEMBL1020706 | 0.79 | ALDH1A1 (0.55) | NOS2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | TAAR1 2621/4885NOS2 3358/4885NOS1 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.